Biosynex specializes in the research, development and manufacturing of fast diagnosis tests on membrane support for health professionals (biologists, clinicians, nurses and midwives). Products are used in the tropical diseases, autoimmune diseases, emergency markers and Infectious diseases fields. The company's activity is organized around 5 areas: - manufacturing of diagnosis tests for own account; - sale of diagnosis tests supplied by other manufacturers of semi-finished products; - research and development services for third party; - sale of licenses; - sale of biological reagents.

Employees

397

Sector

Medical Equipment, Supplies & Distribution

More about the company

Quotes

Date	Price	Change	Volume
26-08-18	€0.9300	-0.64%	531
26-08-17	€0.9360	+0.65%	11,374
26-08-14	€0.9300	-7.00%	37,329
26-08-13	€1.000	0.00%	78,628
26-08-12	€1.000	+9.89%	96,839

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Real-time Euronext Paris 03:00:16 2026-08-18 EDT			5-day change	1st Jan Change
0.9300 ^EUR	-0.64%		+2.20%	+56.04%

08-06	Biosynex hit by cyberattack, operational activity remains intact
06-11	Triple update for Biosynex

Market Cap	17.25M 19.98M 16.19M 14.74M 27.72M 1.91B 28.1M 190M 74.35M 957M 75.03M 73.4M 3.18B	P/E 2024	-0.43x	P/E 2025	-0.19x
Enterprise Value	70.44M 81.6M 66.09M 60.19M 113M 7.8B 115M 775M 304M 3.91B 306M 300M 13B	EV / Sales 2024	0.71x	EV / Sales 2025	0.68x
Free-Float	40.35%	Yield 2024 *	-	Yield 2025	-

08-06	Biosynex hit by cyberattack, operational activity remains intact
06-11	Triple update for Biosynex
06-10	An undisclosed buyer acquired Entire internal molecular biology business from Biosynex SA for ?4 million.	CI
05-25	Paris climbs on hopes of Middle East de-escalation
05-25	Biosynex announces the divestment of its molecular biology business
05-24	An undisclosed buyer signed a binding offer to acquire Entire internal molecular biology business from Biosynex SA for ?4 million.	CI
05-07	Biosynex SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-06	Biosynex SA Auditor Raises 'Going Concern' Doubt	CI
04-21	Thales, Vivendi, Mercialys, GTT... stocks to watch today in Paris
04-21	Biosynex postpones publication of annual accounts
03-24	Abivax, Ekinops, Sanofi... stocks to watch today in Paris
03-24	Observation period extended for Biosynex
02-06	A Biosynex Subsidiary to Receive $1.8 Million Grant

24-10-23	BIOSYNEX SA: CHEMBIO DIAGNOSTICS INC., A SUBSIDIARY OF BIOSYNEX, RECEIVES A GRANT FOR DEVELOPMENT OF A DPP CONGENITAL SYPHILIS ASSAY	EQ
23-04-27	Biosynex Completes Acquisition of Chembio Diagnostics, Inc.	AQ
23-04-13	Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.	AQ
23-03-15	Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.	AQ
23-01-31	Biosynex and Chembio Diagnostics Announce Definitive Acquisition Agreement	AQ

Biosynex Stock

Stocks

ALBIO

FR0011005933

Medical Equipment, Supplies & Distribution

Valuation: Biosynex

Chart: Biosynex

Latest news : Biosynex

Press Releases: Biosynex

News in other languages: Biosynex

Quotes and Performance

Course Extremes

Managers and Directors: Biosynex

Latest insider transactions

Diagnostic & Testing Substances

Financials

Company Profile

Quotes

Income Statement and Estimates

08-07	Bourse : Eutelsat souffre, la tech américaine s'offre un baroud d'honneur nocturne
08-07	L'énigmatique Mister Warsh, le marché du travail et les taux
08-06	Biosynex victime d'une cyberattaque, l'activité opérationnelle préservée
08-06	BIOSYNEX SA: Cyberattaque
07-22	BIOSYNEX SA: CHIFFRE D’AFFAIRES DU 1er SEMESTRE 2026 : 44,1 M€ - PERSPECTIVES

1 day	-0.64%
1 week	+2.20%
Current month	+1.09%
1 month	+2.20%
6 months	+0.65%
Current year	+56.04%

1 week	0.91	1
1 month	0.89	1
Current year	0.56	1.57
1 year	0.46	1.57
3 years	0.46	10.92
5 years	0.46	28.78
10 years	0.46	30.38

Manager	Title	Age	Since
Larry Abensur CEO	Chief Executive Officer	71	2015-06-23
Thierry Paper CTO	Chief Tech/Sci/R&D Officer	63	2014-12-31
Oren Bitton PRN	Corporate Officer/Principal	-	-

Director	Title	Age	Since
Thierry Paper BRD	Director/Board Member	63	2015-06-23
Thomas Lamy BRD	Director/Board Member	-	2015-06-23
Larry Abensur CHM	Chairman	71	2015-06-23

Date	Insider	Type	Main position	Quantity	% Market Cap.
2/15/23	Elie Fraenckel	Buy	Director	2,500	0.0244%
2/15/23	Elie Fraenckel	Buy	Director	2,500	0.0244%
2/28/22	Larry Abensur	Buy	Chief Executive Officer	2,000	0.0180%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOSYNEX	-0.64%	+2.20%	-21.85%	-91.47%	19.98M
GUARDANT HEALTH, INC.	+2.84%	-3.31%	+174.58%	+354.77%	21.7B
BIOMÉRIEUX	+0.14%	-1.49%	-42.85%	-21.41%	9.9B
10X GENOMICS, INC.	+3.39%	-0.99%	+334.06%	+25.49%	7.56B
LANTHEUS HOLDINGS, INC.	-0.04%	-0.07%	+86.25%	+53.22%	6.59B
CARIS LIFE SCIENCES, INC.	-0.78%	-7.56%	-40.74%	-	6.11B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	+0.41%	+4.96%	-12.57%	-6.88%	6B
ANDON HEALTH CO., LTD.	+3.29%	+4.62%	+87.09%	+116.06%	4.7B
DIASORIN S.P.A.	-0.24%	-2.95%	-12.30%	-17.24%	4.27B
AUTOBIO DIAGNOSTICS CO., LTD.	-2.38%	+0.06%	-21.04%	-33.49%	2.79B
Average	+0.60%	+0.17%	+53.06%	+42.12%	6.96B
Weighted average by Cap.	+1.35%	-1.04%	+92.34%	+131.69%

	2024	2025
Net sales	101M 117M 94.91M 86.45M 163M 11.2B 165M 1.11B 436M 5.61B 440M 430M 18.67B	95.19M 110M 89.31M 81.34M 153M 10.54B 155M 1.05B 410M 5.28B 414M 405M 17.57B
Net income	-43.33M -50.19M -40.65M -37.03M -69.62M -4.8B -70.59M -477M -187M -2.4B -188M -184M -8B	-58.22M -67.44M -54.62M -49.75M -93.55M -6.45B -94.85M -640M -251M -3.23B -253M -248M -10.75B
Net Debt	52.94M 61.32M 49.66M 45.23M 85.05M 5.86B 86.23M 582M 228M 2.94B 230M 225M 9.77B	53.19M 61.61M 49.9M 45.45M 85.46M 5.89B 86.65M 585M 229M 2.95B 231M 226M 9.82B